Stanley Bergman - Henry Schein Executive Chairman and CEO

HSIC Stock  USD 74.18  0.40  0.54%   

Chairman

Mr. Stanley M. Bergman serves as Chairman of the Board, Chief Executive Officer of the Company. He was with the Company since 1980, including as Chairman and Chief Executive Officer since 1989 and as a director since 1982. He is also a member of our Executive Management Committee. Mr. Bergman held the position of President of the Company from 1989 to 2005. Mr. Bergman held the position of Executive Vice President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985. Mr. Bergman brings to the Companys Board of Directors management and leadership experience. Mr. Bergman is a wellknown, highly regarded leader in the global health care industry. He has expansive knowledge of the health care industry and macroeconomic global conditions, maintains strategic relationships with chief executives and other senior management in the health care industry throughout the world and brings a unique and valuable perspective to the Board of Directors. During his tenure, Mr. Bergman has led the Company from sales of 600 million in 1995 to 12.5 billion in 2017. Mr. Bergman serves as a board member or advisor for numerous institutions, including New York University College of Dentistry, the University of Pennsylvania School of Dental Medicine, the Columbia University Medical Center, Hebrew University, Tel Aviv University, the University of the Witwatersrand Fund, the World Economic Forums Health Care Governors and the Business Council for International Understanding. Mr. Bergman is also a member of the boards of numerous charitable organizations and active with philanthropic causes and social responsibility activities. Mr. Bergman is a Certified Public Accountant. since 2005.
Age 74
Tenure 19 years
Address 135 Duryea Road, Melville, NY, United States, 11747
Phone631 843 5500
Webhttps://www.henryschein.com

Henry Schein Management Efficiency

The company has return on total asset (ROA) of 0.0453 % which means that it generated a profit of $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0888 %, meaning that it created $0.0888 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2024, Return On Capital Employed is expected to decline to 0.10. In addition to that, Return On Assets is expected to decline to 0.04. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.
The company currently holds 2.74 B in liabilities with Debt to Equity (D/E) ratio of 0.29, which may suggest the company is not taking enough advantage from borrowing. Henry Schein has a current ratio of 1.8, which is within standard range for the sector. Debt can assist Henry Schein until it has trouble settling it off, either with new capital or with free cash flow. So, Henry Schein's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Henry Schein sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Henry to invest in growth at high rates of return. When we think about Henry Schein's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CHAIRMAN Age

Gordon RitterVeeva Systems Class
55
Michael MussallemEdwards Lifesciences Corp
71
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York. Henry Schein operates under Medical Distribution classification in the United States and is traded on NASDAQ Exchange. It employs 22000 people. Henry Schein (HSIC) is traded on NASDAQ Exchange in USA. It is located in 135 Duryea Road, Melville, NY, United States, 11747 and employs 25,000 people. Henry Schein is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Henry Schein Leadership Team

Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary
David McKinley, President Medical Group
Paul Rose, Senior Vice President Global Supply Chain
Norman Matthews, Independent Director
Philip Laskawy, Lead Independent Director
Steven Paladino, CFO, Executive VP and Executive Director
Ronald South, Senior CFO
Barry Alperin, Independent Director
Brad Connett, President - Henry Schein'sU.S. Medical Group
Shira Goodman, Independent Director
Lorelei McGlynn, Senior Vice President - Global Human Resources and Financial Operations
Bradley Sheares, Independent Director
Leonard David, Chief Compliance Officer, Senior Vice President
James Harding, CTO, Senior Vice President
Paul Brons, Independent Director
Lonnie Shoff, President and CEO of Global Animal Health and Strategic Partnerships Group
Gerald Benjamin, Chief Admin. Officer, Executive VP and Director
Bob Minowitz, President International Dental Group
Dianne Rekow, Director
Anne Margulies, Independent Director
Stanley Komaroff, Sr. Advisor
Mark Mlotek, Chief Strategic Officer, Executive VP and Director
Peter McCarthy, President - Global Animal Health Group
Bridget Ross, President of Global Medical Group
Kurt Kuehn, Independent Director
Christopher Pendergast, Senior Vice President CTO
James Breslawski, President, Executive Director and CEO of Global Dental Group
Elizabeth Rekow, Independent Director
Walter Siegel, Senior Vice President General Counsel
Graham Stanley, VP Officer
Jonathan Koch, Senior Vice President and CEO, Global Dental Group
Stanley Bergman, Executive Chairman and CEO
Joseph Herring, Independent Director
Olga Timoshkina, Chief Finance
Karen Prange, Executive Vice President; CEO of Global Animal Health, Medical and Dental Surgical Group
Carolynne Borders, Vice President - Investor Relations
Michael Racioppi, Senior Vice President Chief Merchandising Officer
Donald Kabat, Independent Director
Lawrence Bacow, Director
Louis Sullivan, Independent Director
Bradford Connett, Chief Group
Carol Raphael, Independent Director

Henry Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Henry Schein Investors Sentiment

The influence of Henry Schein's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Henry. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Henry Schein's public news can be used to forecast risks associated with an investment in Henry. The trend in average sentiment can be used to explain how an investor holding Henry can time the market purely based on public headlines and social activities around Henry Schein. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Henry Schein's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Henry Schein's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Henry Schein's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Henry Schein.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Henry Schein in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Henry Schein's short interest history, or implied volatility extrapolated from Henry Schein options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Henry Stock analysis

When running Henry Schein's price analysis, check to measure Henry Schein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Henry Schein is operating at the current time. Most of Henry Schein's value examination focuses on studying past and present price action to predict the probability of Henry Schein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Henry Schein's price. Additionally, you may evaluate how the addition of Henry Schein to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Henry Schein's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.62)
Earnings Share
3.16
Revenue Per Share
94.466
Quarterly Revenue Growth
(0.10)
Return On Assets
0.0453
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.